About this trial
This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.
Eligibility criteria
Qualifiers
Age 18 years or older
Scheduled for clinical brain MRI with gadolinium contrast
Known or suspected brain metastases
Able to provide informed consent
Disqualifiers
Contraindications to MRI
Known allergy or contraindication to gadolinium-based contrast agents
Renal impairment (eGFR < 30 mL/min/1.73m²)
Pregnant or breastfeeding
Trial design
Treatments tested in this trial
- Novel Gadolinium-Weighted MRI Sequence